Transforming growth factor-β1 enhances proliferative and metastatic potential by up-regulating lymphoid enhancer-binding factor 1/integrin αMβ2 in human renal cell carcinoma

  • 62 Accesses


Renal cell carcinoma (RCC) is a kind of malignant tumor with high recurrence, and it is urgent to find molecular markers for diagnosis and prognosis of RCC. Our study investigated the expression and function of integrin αMβ2 in RCC cells, aiming to understand the role of integrin αMβ2 in RCC and develop new therapeutic target for RCC. Overexpression and knockdown of lymphoid enhancer-binding factor 1 (LEF1) were performed using vector containing full-length cDNA and via siRNA technology, respectively. The expressions of mRNA and protein were detected by RT-PCR and Western blot, respectively. Proliferation of RCC cell was analyzed using WST-1 assay, and metastasis of RCC cell was evaluated using the transwell system. Our results demonstrated that LEF1 and integrin αMβ2 were up-regulated in RCC cells via TGF-β1-dependent mechanism, and LEF1 together with β-catenin directly increased integrin αMβ2 level. On the other hand, TGF-β1-induced proliferation, migration and invasion were suppressed by function-blocking antibody against integrin αMβ2 in RCC cells. In addition, integrin αMβ2 is crucial for LEF1 mediated cell invasion by regulating MMP-2, MMP-9 and calpain-2 secretion in RCC cells. LEF1/integrin αMβ2 expression was regulated by TGF-β1, and LEF1/integrin αMβ2 was involved in TGF-β1’s improvement effects on the proliferation and metastasis of RCC. Blocking integrin αMβ2 activity could be a therapeutic option for patients with advanced RCC.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6


  1. 1.

    Porta C, Paglino C, Grunwald V (2014) Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer 111(6):1047–1053.

  2. 2.

    Chiong E, Tay MH, Tan MH, Kumar S, Sim HG, Teh BT, Umbas R, Chau NM (2012) Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol 13(11):e482–491.

  3. 3.

    Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ (2005) Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 23(12):2763–2771.

  4. 4.

    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590.

  5. 5.

    Wu D, Xu Y, Ding T, Zu Y, Yang C, Yu L (2017) Pairing of integrins with ECM proteins determines migrasome formation. Cell Res 27(11):1397–1400.

  6. 6.

    Barczyk M, Carracedo S, Gullberg D (2010) Integrins. Cell Tissue Res 339(1):269–280.

  7. 7.

    Rucci N, Teti A (2016) The “love-hate” relationship between osteoclasts and bone matrix. Matrix Biol 52–54:176–190.

  8. 8.

    Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110(6):673–687.

  9. 9.

    Streuli CH (2009) Integrins and cell-fate determination. J Cell Sci 122(Pt 2):171–177.

  10. 10.

    Abram CL, Lowell CA (2009) The ins and outs of leukocyte integrin signaling. Annu Rev Immunol 27:339–362.

  11. 11.

    Prieto J, Eklund A, Patarroyo M (1994) Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages. Cell Immunol 156(1):191–211.

  12. 12.

    Shang XZ, Issekutz AC (1997) Beta 2 (CD18) and beta 1 (CD29) integrin mechanisms in migration of human polymorphonuclear leucocytes and monocytes through lung fibroblast barriers: shared and distinct mechanisms. Immunology 92(4):527–535.

  13. 13.

    Graff JC, Jutila MA (2007) Differential regulation of CD11b on gammadelta T cells and monocytes in response to unripe apple polyphenols. J Leukoc Biol 82(3):603–607.

  14. 14.

    Shi C, Sakuma M, Mooroka T, Liscoe A, Gao H, Croce KJ, Sharma A, Kaplan D, Greaves DR, Wang Y, Simon DI (2008) Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function. Blood 112(12):4699–4711.

  15. 15.

    Shi C, Zhang X, Chen Z, Sulaiman K, Feinberg MW, Ballantyne CM, Jain MK, Simon DI (2004) Integrin engagement regulates monocyte differentiation through the forkhead transcription factor Foxp1. J Clin Investig 114(3):408–418.

  16. 16.

    Xue ZH, Zhao CQ, Chua GL, Tan SW, Tang XY, Wong SC, Tan SM (2010) Integrin alphaMbeta2 clustering triggers phosphorylation and activation of protein kinase C delta that regulates transcription factor Foxp1 expression in monocytes. J Immunol 184(7):3697–3709.

  17. 17.

    Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoeft T, Higuchi T, Beissert S, Wethmar K, Scharffetter-Kochanek K, Vestweber D, Grabbe S (2007) Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood 109(2):661–669.

  18. 18.

    Skoberne M, Somersan S, Almodovar W, Truong T, Petrova K, Henson PM, Bhardwaj N (2006) The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of human dendritic-cell immunostimulatory function. Blood 108(3):947–955.

  19. 19.

    Santoso S, Sachs UJ, Kroll H, Linder M, Ruf A, Preissner KT, Chavakis T (2002) The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med 196(5):679–691.

  20. 20.

    Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, Lopez JA (2000) Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 192(2):193–204.

  21. 21.

    Waterman ML, Fischer WH, Jones KA (1991) A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer. Genes Dev 5(4):656–669.

  22. 22.

    Travis A, Amsterdam A, Belanger C, Grosschedl R (1991) LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]. Genes Dev 5(5):880–894.

  23. 23.

    Liu LJ, Yu JJ, Xu XL (2017) MicroRNA-93 inhibits apoptosis and promotes proliferation, invasion and migration of renal cell carcinoma ACHN cells via the TGF-beta/Smad signaling pathway by targeting RUNX3. Am J Transl Res 9(7):3499–3513

  24. 24.

    Sjolund J, Bostrom AK, Lindgren D, Manna S, Moustakas A, Ljungberg B, Johansson M, Fredlund E, Axelson H (2011) The notch and TGF-beta signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS ONE 6(8):e23057.

  25. 25.

    Bostrom AK, Lindgren D, Johansson ME, Axelson H (2013) Effects of TGF-beta signaling in clear cell renal cell carcinoma cells. Biochem Biophys Res Commun 435(1):126–133.

  26. 26.

    Huang F, Newman E, Theodorescu D, Kerbel RS, Friedman E (1995) Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. Cell Growth Differ 6(12):1635–1642

  27. 27.

    Wang J, Chen J, Zhang K, Zhao Y, Nor JE, Wu J (2011) TGF-beta1 regulates the invasive and metastatic potential of mucoepidermoid carcinoma cells. J Oral Pathol Med 40(10):762–768.

  28. 28.

    Ananth S, Knebelmann B, Gruning W, Dhanabal M, Walz G, Stillman IE, Sukhatme VP (1999) Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res 59(9):2210–2216

  29. 29.

    Lebdai S, Verhoest G, Parikh H, Jacquet SF, Bensalah K, Chautard D, Rioux-Leclercq N, Azzouzi AR, Bigot P (2015) Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma. Urol Oncol 33(2):69.e11–69.e68.

  30. 30.

    Huang W, Cen S, Kang XL, Wang WF, Wang Y, Chen X (2016) TGF-beta1-induced Fascin1 promotes cell invasion and metastasis of human 786-0 renal carcinoma cells. Acta Histochem 118(2):144–151.

  31. 31.

    Edlund S, Lee SY, Grimsby S, Zhang S, Aspenstrom P, Heldin CH, Landstrom M (2005) Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis. Mol Cell Biol 25(4):1475–1488.

  32. 32.

    Feldkoren B, Hutchinson R, Rapoport Y, Mahajan A, Margulis V (2017) Integrin signaling potentiates transforming growth factor-beta 1 (TGF-beta1) dependent down-regulation of E-Cadherin expression—important implications for epithelial to mesenchymal transition (EMT) in renal cell carcinoma. Exp Cell Res 355(2):57–66.

  33. 33.

    Yeh YC, Wei WC, Wang YK, Lin SC, Sung JM, Tang MJ (2010) Transforming growth factor-{beta}1 induces Smad3-dependent {beta}1 integrin gene expression in epithelial-to-mesenchymal transition during chronic tubulointerstitial fibrosis. Am J Pathol 177(4):1743–1754.

  34. 34.

    Li TW, Ting JH, Yokoyama NN, Bernstein A, van de Wetering M, Waterman ML (2006) Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol Cell Biol 26(14):5284–5299.

  35. 35.

    Santiago L, Daniels G, Wang D, Deng FM, Lee P (2017) Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. Am J Cancer Res 7(6):1389–1406

  36. 36.

    Vallee A, Lecarpentier Y, Vallee JN (2019) Targeting the canonical WNT/beta-catenin pathway in cancer treatment using non-steroidal anti-inflammatory drugs. Cells.

  37. 37.

    Guo X, Wang XF (2009) Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 19(1):71–88.

  38. 38.

    Amini Nik S, Ebrahim RP, Van Dam K, Cassiman JJ, Tejpar S (2007) TGF-beta modulates beta-Catenin stability and signaling in mesenchymal proliferations. Exp Cell Res 313(13):2887–2895.

  39. 39.

    Liu W, Rui H, Wang J, Lin S, He Y, Chen M, Li Q, Ye Z, Zhang S, Chan SC, Chen YG, Han J, Lin SC (2006) Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. EMBO J 25(8):1646–1658.

  40. 40.

    Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, Sheppard D (1999) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96(3):319–328.

  41. 41.

    Galliher AJ, Schiemann WP (2006) Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8(4):R42.

  42. 42.

    Mamuya FA, Duncan MK (2012) aV integrins and TGF-beta-induced EMT: a circle of regulation. J Cell Mol Med 16(3):445–455.

  43. 43.

    Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10(1):9–22.

  44. 44.

    Belo VA, Guimaraes DA, Castro MM (2015) Matrix metalloproteinase 2 as a potential mediator of vascular smooth muscle cell migration and chronic vascular remodeling in hypertension. J Vasc Res 52(4):221–231.

  45. 45.

    Sato A, Nagase H, Obinata D, Fujiwara K, Fukuda N, Soma M, Yamaguchi K, Kawata N, Takahashi S (2013) Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma. Int J Oncol 43(5):1441–1446.

  46. 46.

    Chen SJ, Yao XD, Peng BO, Xu YF, Wang GC, Huang J, Liu M, Zheng JH (2016) Epigallocatechin-3-gallate inhibits migration and invasion of human renal carcinoma cells by downregulating matrix metalloproteinase-2 and matrix metalloproteinase-9. Exp Ther Med 11(4):1243–1248.

  47. 47.

    Jang HS, Lal S, Greenwood JA (2010) Calpain 2 is required for glioblastoma cell invasion: regulation of matrix metalloproteinase 2. Neurochem Res 35(11):1796–1804.

  48. 48.

    Li X, Yang Y, Hu Y, Dang D, Regezi J, Schmidt BL, Atakilit A, Chen B, Ellis D, Ramos DM (2003) Alphavbeta6-Fyn signaling promotes oral cancer progression. J Biol Chem 278(43):41646–41653.

  49. 49.

    Niu J, Gu X, Turton J, Meldrum C, Howard EW, Agrez M (1998) Integrin-mediated signalling of gelatinase B secretion in colon cancer cells. Biochem Biophys Res Commun 249(1):287–291.

  50. 50.

    Li Y, Ren Z, Wang Y, Dang YZ, Meng BX, Wang GD, Zhang J, Wu J, Wen N (2018) ADAM17 promotes cell migration and invasion through the integrin beta1 pathway in hepatocellular carcinoma. Exp Cell Res 370(2):373–382.

  51. 51.

    Yang L, Song X, Zhu J, Li M, Ji Y, Wu F, Chen Y, Cui X, Hu J, Wang L, Cao Y, Wei Y, Zhang W, Li F (2017) Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. Int J Oncol 51(1):378–388.

  52. 52.

    Peng X, Zhang Q, Zeng Y, Li J, Wang L, Ai P (2015) Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression. Cancer Chemother Pharmacol 76(6):1173–1184.

  53. 53.

    Chen YS, Meng F, Li HL, Liu QH, Hou PF, Bai J, Zheng JN (2016) Dicer suppresses MMP-2-mediated invasion and VEGFA-induced angiogenesis and serves as a promising prognostic biomarker in human clear cell renal cell carcinoma. Oncotarget 7(51):84299–84313.

  54. 54.

    Zhang YE (2017) Non-Smad signaling pathways of the TGF-beta family. Cold Spring Harb Perspect Biol.

Download references

Author information

Correspondence to Donghao Shang.

Ethics declarations

Conflict of interest

All the authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Shang, D. Transforming growth factor-β1 enhances proliferative and metastatic potential by up-regulating lymphoid enhancer-binding factor 1/integrin αMβ2 in human renal cell carcinoma. Mol Cell Biochem 465, 165–174 (2020).

Download citation


  • Renal
  • Cell carcinoma
  • TGF-β1
  • LEF1
  • Integrin
  • Proliferation
  • Metastasis